IDEXX Laboratories, Inc. files its Annual Report describing a diversified diagnostics business focused on companion animal health, water quality, and livestock, poultry and dairy testing, plus a smaller human point-of-care line. The company highlights extensive use of AI across analyzers, imaging and software, and a cloud ecosystem that connects in-clinic instruments with reference labs and telemedicine.
IDEXX reports $251.2 million of 2025 research and development expense, or 5.8% of consolidated revenue, up from $219.8 million (5.6%) in 2024 and $191.0 million (5.2%) in 2023. It notes significant regulatory oversight globally, reliance on some sole‑source suppliers, increasing PFAS and AI regulation, and strong human‑capital programs supporting about 11,000 employees in 34 countries.
IDEXX Laboratories Executive Vice President Michael G. Erickson reported multiple stock option exercises and related share sales. On February 17, 2026 and February 19, 2026, he exercised incentive and non-qualified stock options and received IDEXX common shares.
On February 17, 2026, he then sold 5,371 shares of common stock in open-market transactions at weighted average prices ranging from about $623.28 to $629.8625 per share. After these transactions, he directly held 12,693.351 shares of IDEXX common stock, including 184 vested but deferred restricted stock units.
IDEXX Laboratories director Sophie V. Vandebroek exercised a non-qualified stock option for 945 shares of common stock on February 17, 2026 at an exercise price of $333.90 per share, converting the derivative into common stock held directly.
On the same date, she executed open-market sales of 945 and 519 common shares at weighted average prices of $628.646 and $628.56 per share, respectively. After these transactions, she held 648 IDEXX common shares directly and 8,173 shares indirectly through the Sophie V. Vandebroek Revocable Trust.
IDEXX Laboratories executive Sharon E. Underberg reported multiple equity award activities. On February 12, 2026, she received grants of 3,738 non-qualified stock options, 162 incentive stock options, and 891 restricted stock units (RSUs), with the options and RSUs vesting in scheduled installments beginning February 14, 2027 and one option grant vesting on February 14, 2030.
On February 14, 2026, several prior RSU awards vested, converting into a total of 832 shares of common stock. To cover tax obligations, 251 shares of common stock were withheld at a price of $629.35 per share. After these transactions, she directly owned 6,940.654 shares of IDEXX common stock.
Smith Martin Alexander reported multiple insider transaction types in a Form 4 filing for IDXX. The filing lists transactions totaling 10,715 shares at a weighted average price of $629.35 per share. Following the reported transactions, holdings were 188 shares.
IDEXX Laboratories Executive Vice President Michael Schreck reported a series of equity compensation transactions. On February 12, 2026, he was granted 4,625 non-qualified stock options and 162 incentive stock options, along with 1,094 and 1,620 restricted stock units (RSUs), all at a stated price of 0.0000 per share. Footnotes state these options become exercisable in installments beginning February 14, 2027 and on February 14, 2030, while the RSUs vest over three or four annual installments starting February 14, 2027 and February 14, 2026.
On February 14, 2026, multiple RSU awards vested and were converted into an aggregate of 1,959 shares of common stock at a stated price of 0.0000 per share. In a separate transaction coded “F,” 876 common shares at 629.35 per share were disposed of to satisfy tax withholding, leaving 3,088.709 common shares owned directly.
MAZELSKY JONATHAN JAY reported multiple insider transaction types in a Form 4 filing for IDXX. The filing lists transactions totaling 18,436 shares at a weighted average price of $629.35 per share. Following the reported transactions, holdings were 1,099 shares.
Lane Michael reported multiple insider transaction types in a Form 4 filing for IDXX. The filing lists transactions totaling 10,810 shares at a weighted average price of $629.35 per share. Following the reported transactions, holdings were 1,101 shares.
IDEXX Laboratories Executive Vice President Michael Perkins Johnson reported equity award activity and related share settlements. He received stock options for 3,207 shares (non-qualified) and 162 shares (incentive) on February 12, 2026, along with 770 restricted stock units (RSUs), all at a grant price of $0.00 per share.
On February 14, 2026, 176, 179 and 218 RSUs were exercised into the same number of common shares at $0.00 per share. In a separate tax-withholding disposition, 178 common shares were delivered at $629.35 per share to cover tax obligations, leaving him with 2,794.687 directly owned common shares.